Press Releases

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date	Title and Summary	Additional Formats
Toggle SummaryApr 4, 2018	Amarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on REDUCE-IT Cardiovascular Outcomes Study Progress and Vascepa® Promotion Initiatives Over 97% of Final Patient Visits in REDUCE-IT Completed or Scheduled for Near-Term Completion	View HTML Amarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on REDUCE-IT Cardiovascular Outcomes Study Progress and Vascepa® Promotion Initiatives 103.8 KB
Toggle SummaryApr 4, 2018	Amarin's REDUCE-IT Cardiovascular Outcomes Study Reaches 100% Mark for Estimated Onset of Target Primary Major Adverse Cardiovascular Events On Track to Report REDUCE-IT Results Before the End of Q3 2018	View HTML Amarin's REDUCE-IT Cardiovascular Outcomes Study Reaches 100% Mark for Estimated Onset of Target Primary Major Adverse Cardiovascular Events 100.4 KB
Toggle SummaryMar 29, 2018	Amarin Sponsors Two Scientific Presentations Scheduled for National Kidney Foundation 2018 Spring Clinical Meetings BEDMINSTER, N.J. and DUBLIN, Ireland , March 29, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, is supporting the presentation of two accepted scientific	View HTML Amarin Sponsors Two Scientific Presentations Scheduled for National Kidney Foundation 2018 Spring Clinical Meetings 148.1 KB
Toggle SummaryMar 28, 2018	Amarin to Present at the H.C. Wainwright Annual Global Life Sciences Conference BEDMINSTER, N.J. and DUBLIN, Ireland , March 28, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.	View HTML Amarin to Present at the H.C. Wainwright Annual Global Life Sciences Conference 20.1 KB
Toggle SummaryMar 27, 2018	Amarin Commemorates National Triglycerides Day on March 28 Increasing Awareness of Triglycerides and a Call to Action for People to Talk to Their Doctors, Nurses & Pharmacists About Their Triglyceride Levels	View HTML Amarin Commemorates National Triglycerides Day on March 28 24.6 KB
Toggle SummaryMar 21, 2018	Amarin Announces First Middle East Approval for Vascepa® Lebanon Approves Vascepa for Sale, First in Series of Anticipated Approvals	View HTML Amarin Announces First Middle East Approval for Vascepa® 96.8 KB
Toggle SummaryMar 12, 2018	Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipids and Inflammatory Markers in Patients With Persistent High Triglycerides and Elevated High-Sensitivity C-Reactive Protein (hsCRP) BEDMINSTER , N.J. and DUBLIN, Ireland , March 12, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular (CV) health, presented an analysis showing that, consistent with	View HTML Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipids and Inflammatory Markers in Patients With Persistent High Triglycerides and Elevated High-Sensitivity C-Reactive Protein (hsCRP) 106.6 KB
Toggle SummaryMar 12, 2018	Real-World Data Supports Association Between Elevated Triglyceride Levels and Increased Cardiovascular Events and Healthcare Costs BEDMINSTER, N.J. and DUBLIN, Ireland , March 12, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular (CV) health, announced the presentation of a poster today at the	View HTML Real-World Data Supports Association Between Elevated Triglyceride Levels and Increased Cardiovascular Events and Healthcare Costs 104.9 KB
Toggle SummaryMar 5, 2018	Amarin Announces Closing of Underwriter's Purchase of Additional Shares BEDMINSTER, N.J. , and DUBLIN, Ireland , March 05, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that, in connection with its previously announced underwritten public offering of American Depositary Shares ("ADSs"), it has issued 1,438,356 additional ADSs, pursuant	View HTML Amarin Announces Closing of Underwriter's Purchase of Additional Shares 21.7 KB
Toggle SummaryMar 1, 2018	Amarin Announces Start of Final Clinical Site Visits in the REDUCE-IT Cardiovascular Outcomes Study Study Results Anticipated to be Released by End of Q3 2018	View HTML Amarin Announces Start of Final Clinical Site Visits in the REDUCE-IT Cardiovascular Outcomes Study 98.9 KB

Investor Relations / Press Releases

Press Releases

Amarin Corporation